Elanco Animal Health Past Earnings Performance
Past criteria checks 2/6
Elanco Animal Health has been growing earnings at an average annual rate of 12.8%, while the Pharmaceuticals industry saw earnings growing at 9.8% annually. Revenues have been growing at an average rate of 4.6% per year. Elanco Animal Health's return on equity is 6.4%, and it has net margins of 9.7%.
Key information
12.79%
Earnings growth rate
14.18%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | 4.65% |
| Return on equity | 6.41% |
| Net Margin | 9.68% |
| Next Earnings Update | 05 Nov 2025 |
Recent past performance updates
Recent updates
Elanco Animal Health's (NYSE:ELAN) Profits Appear To Have Quality Issues
Aug 20
Elanco Animal Health Q2: Rising Innovation Revenue, Initiate At Buy
Aug 07Elanco Animal Health (NYSE:ELAN) Has A Somewhat Strained Balance Sheet
Jul 21Elanco Animal Health Incorporated (NYSE:ELAN) Held Back By Insufficient Growth Even After Shares Climb 39%
May 28The Market Doesn't Like What It Sees From Elanco Animal Health Incorporated's (NYSE:ELAN) Revenues Yet As Shares Tumble 25%
Apr 09Elanco Animal Health: Even Cheaper, Still Not A Buy
Mar 31
Zenrelia And Credelio Quattro Launches Will Expand Market Presence But FX Headwinds May Impact Earnings
Strategic divestment and product launches are enhancing financial stability by reducing debt and increasing investment capacity, aiming to improve net margins.Elanco Animal Health: Building On Success
Jan 15Elanco Animal Health (NYSE:ELAN) Takes On Some Risk With Its Use Of Debt
Jan 08Elanco Animal Health Incorporated's (NYSE:ELAN) Business And Shares Still Trailing The Industry
Dec 12Elanco Animal Health's (NYSE:ELAN) Solid Profits Have Weak Fundamentals
Nov 15Elanco Animal Health: Not Expensive, But Debt Remains An Issue
Nov 08Elanco Animal Health: Positioned For Success
Aug 16Elanco Animal Health: Pipeline Concerns Appear Overblown
Jun 30Elanco Animal Health: At Least Fully Valued After Rally
Jun 05Elanco Animal Health: A Solid Sale Addresses Leverage
Feb 09Revenue & Expenses Breakdown
How Elanco Animal Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 25 | 4,484 | 434 | 1,358 | 354 |
| 31 Mar 25 | 4,427 | 373 | 1,312 | 351 |
| 31 Dec 24 | 4,439 | 338 | 1,308 | 344 |
| 30 Sep 24 | 4,454 | 205 | 1,301 | 342 |
| 30 Jun 24 | 4,492 | -1,255 | 1,291 | 341 |
| 31 Mar 24 | 4,365 | -1,302 | 1,290 | 333 |
| 31 Dec 23 | 4,417 | -1,231 | 1,280 | 327 |
| 30 Sep 23 | 4,367 | -1,144 | 1,289 | 328 |
| 30 Jun 23 | 4,324 | -113 | 1,273 | 320 |
| 31 Mar 23 | 4,442 | -26 | 1,263 | 321 |
| 31 Dec 22 | 4,411 | -78 | 1,259 | 321 |
| 30 Sep 22 | 4,538 | -132 | 1,290 | 333 |
| 30 Jun 22 | 4,644 | -171 | 1,334 | 349 |
| 31 Mar 22 | 4,748 | -371 | 1,372 | 361 |
| 31 Dec 21 | 4,764 | -483 | 1,395 | 369 |
| 30 Sep 21 | 4,791 | -698 | 1,431 | 390 |
| 30 Jun 21 | 4,550 | -729 | 1,373 | 384 |
| 31 Mar 21 | 3,857 | -572 | 1,153 | 349 |
| 31 Dec 20 | 3,271 | -574 | 988 | 329 |
| 30 Sep 20 | 2,921 | -246 | 810 | 281 |
| 30 Jun 20 | 2,802 | -101 | 719 | 263 |
| 31 Mar 20 | 2,998 | -13 | 759 | 273 |
| 31 Dec 19 | 3,071 | 68 | 757 | 270 |
| 30 Sep 19 | 3,083 | 94 | 759 | 264 |
| 30 Jun 19 | 3,073 | 144 | 746 | 253 |
| 31 Mar 19 | 3,062 | 45 | 736 | 246 |
| 31 Dec 18 | 3,067 | 87 | 735 | 247 |
| 30 Sep 18 | 3,022 | -91 | 747 | 248 |
| 30 Jun 18 | 2,958 | -172 | 763 | 250 |
| 31 Mar 18 | 2,906 | -174 | 766 | 253 |
| 31 Dec 17 | 2,889 | -311 | 780 | 252 |
| 31 Dec 16 | 2,914 | -48 | 785 | 266 |
| 31 Dec 15 | 2,909 | -211 | 916 | 291 |
Quality Earnings: ELAN has a large one-off gain of $606.0M impacting its last 12 months of financial results to 30th June, 2025.
Growing Profit Margin: ELAN became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ELAN has become profitable over the past 5 years, growing earnings by 12.8% per year.
Accelerating Growth: ELAN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ELAN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.4%).
Return on Equity
High ROE: ELAN's Return on Equity (6.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/28 13:03 |
| End of Day Share Price | 2025/10/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elanco Animal Health Incorporated is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Ardalan Arfaei | BMO Capital Markets Equity Research |
| Navann Ty Dietschi | BNP Paribas |